Since 1993, the AACR has awarded more than $542 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and young adults. Dr. Amit Sabnis, recipient of the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research, and his research team demonstrated the therapeutic potential of bi-steric mTORC1 inhibitors in FOXO1 fusion positive RMS.
Tuomas Tammela, MD, PhD shared how his 2018 AACR NextGen Grant led to the discovery of a new particularly malignant cell state in lung cancer. He lauds the benefits of grants such as the AACR Next Gen grants that provide robust support for research on fundamental biology.
Insights from AACR grant recipients reveal how the AACR Cancer Health Disparities Conference is more than just a transfer of information by serving as a backdrop for conversations among individuals minority and non-minority alike, bound by a singular commitment to provide cancer cures for all.
The AACR-Bayer Innovation and Discovery Grants sought to uncover new treatment options for cancers with high unmet medical need and encourage translation of ideas from basic research into novel drugs. Surgical oncologist, Rosa Hwang, MD, received the grant in 2016, helping her pursue a new therapeutic target in pancreatic cancer.
AACR Special Conference “Rethinking DCIS: An Opportunity for Prevention” Plenary Session Speaker Fariba Behbod, Pharm D, PhD, received the AACR-Breast Cancer Research Foundation for Translational Breast Cancer Research award in 2014, when she was an Assistant Professor at the Kansas University Medical Center Research Institute. Now a Full Professor, she speaks on the impact of the AACR grant on her research and career.
One of the 2021 AACR-Novocure Tumor Treating Fields Research Grant recipients, Maurizio D’Incalci, MD, seeks to elucidate the molecular mechanisms behind the combinatorial efficacy of TTFields /chemotherapy.
Chemotherapy-induced cognitive impairment (CICI), also known as chemobrain, can affect up to 75% of patients during treatment. Recipient of the 2019 The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Alfredo Oliveros, PhD, and his colleagues showed that inhibiting adenosine A2A receptor signaling can prevent cisplatin-induced cognitive impairment.
By Christina Leah B. Kline, PhD Participating at the biggest cancer meeting in the world from the comforts of your lab desk or your home has its perks. Yet, the 2022 AACR Annual Meeting proved that meeting colleagues face...
The AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway encouraged and supported a physician-scientist to conduct cancer research on the HER Family Pathway and to establish a successful career path in this field. Christine...
The AACR-CRUK Transatlantic Fellowships support promising postdoctoral cancer researchers at US and UK research institutions to carry out a portion of their postdoctoral research at a research institution in the UK or the US, respectively. The AACR-CRUK fellows share the impact of this unique program on their careers and research.